156 related articles for article (PubMed ID: 8852025)
21. [Allergic reactions in treatment with L-asparaginase. Significance of specific IgE antibodies].
Körholz D; Wahn U; Jürgens H; Wahn V
Monatsschr Kinderheilkd; 1990 Jan; 138(1):23-5. PubMed ID: 2314401
[TBL] [Abstract][Full Text] [Related]
22. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
23. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia.
Woo MH; Hak LJ; Storm MC; Evans WE; Sandlund JT; Rivera GK; Wang B; Pui CH; Relling MV
Leukemia; 1998 Oct; 12(10):1527-33. PubMed ID: 9766495
[TBL] [Abstract][Full Text] [Related]
24. Significance of serum immunoglobulin G for leukocytosis and prognosis in childhood B-lineage acute lymphoblastic leukemia.
Potapnev MP; Belevtsev MV; Bortkevich LG; Grinev VV; Martsev SP; Kravchuk ZI; Migal NV; Aleinikova OV
Pediatr Blood Cancer; 2004 May; 42(5):421-6. PubMed ID: 15049013
[TBL] [Abstract][Full Text] [Related]
25. Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000.
Attarbaschi A; Mann G; Kronberger M; Witt V; Gadner H; Dworzak M
Klin Padiatr; 2003; 215(6):321-6. PubMed ID: 14677096
[TBL] [Abstract][Full Text] [Related]
26. A fluorometric assay for L-asparaginase activity and monitoring of L-asparaginase therapy.
Ylikangas P; Mononen I
Anal Biochem; 2000 Apr; 280(1):42-5. PubMed ID: 10805519
[TBL] [Abstract][Full Text] [Related]
27. [Acute pancreatitis in children with acute lymphoblastic leukemia treated with L-asparaginase].
Wlazłowski M; Celińska W; Maciejka-Kapuścińska L; Płoszyńska A; Idczak E
Pol Tyg Lek; 1994 Mar 21-28; 49(12-13):296-7. PubMed ID: 7808958
[TBL] [Abstract][Full Text] [Related]
28. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
[TBL] [Abstract][Full Text] [Related]
29. Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL.
Nowak-Göttl U; Werber G; Ziemann D; Ahlke E; Boos J
Haematologica; 1996; 81(2):127-31. PubMed ID: 8641640
[TBL] [Abstract][Full Text] [Related]
30. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
[TBL] [Abstract][Full Text] [Related]
31. [Immunological aspects in the L-asparaginase treatment of children with lymphoproliferative diseases].
Zajaçzkowski J; Halikowski B; Pituch A; Legutko L; Pajdak E
Folia Haematol Int Mag Klin Morphol Blutforsch; 1976; 103(1):21-8. PubMed ID: 58815
[TBL] [Abstract][Full Text] [Related]
32. The ex vivo production of ammonia predicts L-asparaginase biological activity in children with acute lymphoblastic leukemia.
Watanabe S; Miyake K; Ogawa C; Matsumoto H; Yoshida K; Hirabayashi S; Hasegawa D; Inoue T; Kizu J; Machida R; Ohara A; Hosoya R; Manabe A
Int J Hematol; 2009 Oct; 90(3):347-352. PubMed ID: 19768519
[TBL] [Abstract][Full Text] [Related]
33. L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children.
Hourani R; Abboud M; Hourani M; Khalifeh H; Muwakkit S
Neuropediatrics; 2008 Feb; 39(1):46-50. PubMed ID: 18504683
[TBL] [Abstract][Full Text] [Related]
34. ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia.
Wang B; Hak LJ; Relling MV; Pui CH; Woo MH; Storm MC
J Immunol Methods; 2000 May; 239(1-2):75-83. PubMed ID: 10821949
[TBL] [Abstract][Full Text] [Related]
35. Blood lipid profiles in children with acute lymphoblastic leukemia.
Halton JM; Nazir DJ; McQueen MJ; Barr RD
Cancer; 1998 Jul; 83(2):379-84. PubMed ID: 9669823
[TBL] [Abstract][Full Text] [Related]
36. Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.
Jörck C; Kiess W; Weigel JF; Mütze U; Bierbach U; Beblo S
Pediatr Hematol Oncol; 2011 Feb; 28(1):3-9. PubMed ID: 20615069
[TBL] [Abstract][Full Text] [Related]
37. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
Tram Henriksen L; Gottschalk Højfeldt S; Schmiegelow K; Frandsen TL; Skov Wehner P; Schrøder H; Klug Albertsen B;
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28660740
[TBL] [Abstract][Full Text] [Related]
38. Immunological aspects of L-asparaginase treatment in children with lymphoproliferative disease.
Zajaczkowski J; Pituch A; Legutko L; Pajak E
Helv Paediatr Acta; 1976 Jan; 30(4-5):441-6. PubMed ID: 1060605
[TBL] [Abstract][Full Text] [Related]
39. [Hyperglycemia as a side effect of using L-asparaginase in children with acute lymphoblastic leukemia (ALL].
Brodkiewicz A; Kamieńska E; Urasiński T; Peregud-Pogorzelski J
Acta Haematol Pol; 1995; 26(1):99-101. PubMed ID: 7747569
[TBL] [Abstract][Full Text] [Related]
40. L-asparaginase induced intracranial haemorrhage in acute lymphoblastic leukemia.
Lim HL; Teo CP; Wong K; Kueh YK
Singapore Med J; 1998 Feb; 39(2):76-8. PubMed ID: 9652181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
